X4 Pharmaceuticals (XFOR) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Strategic focus and operational changes

• Leadership has refocused efforts on developing mavorixafor for chronic neutropenia, reducing costs and headcount to align with this goal.

• Commercialization of mavorixafor for WHIM syndrome has been deprioritized due to limited revenue, but drug access for patients remains.

• The team has shifted resources from commercial activities to patient recruitment for clinical trials, leveraging AI and fieldwork to identify eligible patients.

• Operational improvements have increased enrollment rates in the 4WARD Phase III trial, with a target to complete enrollment by the end of Q3.

Clinical development and trial design

• Mavorixafor is being evaluated in the 4WARD Phase III trial for chronic neutropenia, enrolling 176 patients randomized 1:1 to mavorixafor or placebo, with or without G-CSF.

• Eligibility requires patients to have had at least two infections in the past year; primary endpoints are ANC increase and infection reduction.

• About 40% of trial participants are on G-CSF, but the trial does not allow G-CSF dose titration; a separate Phase II study is planned to address this.

• Long-term safety and efficacy are being monitored, with no new safety signals observed and some GI toxicity managed symptomatically.

Market opportunity and competitive landscape

• Market research estimates 15,000 patients in the US with symptomatic, severe or moderate chronic neutropenia; initial target is to treat about 5,000.

• Mavorixafor offers an oral alternative to G-CSF, addressing unmet needs such as bone pain, risk of malignancy, and poor tolerability.

• No significant competitors are currently identified in the CXCR4 inhibitor space for this indication.

• Pricing is expected to be at a premium due to the rare disease focus and potential to reduce costly hospitalizations, though lower than current $500,000 levels.